Proliferating cell nuclear antigen clamp associated factor, a potential proto-oncogene with increased expression in malignant gastrointestinal tumors.
Proliferating cell nuclear antigen clamp associated factor, a potential proto-oncogene with increased expression in malignant gastrointestinal tumors.
复制标题
增殖细胞核抗原夹相关因子，一种潜在的原癌基因，在胃肠道恶性肿瘤中表达增加。
DOI：
10.4251/wjgo.v13.i10.1425
复制
发表时间：
2021-10-15
影响因子：
3
通讯作者：
Zhu F
中科院分区：
文献类型：
--
作者：
Liu LJ;Liao JM;Zhu F
Gastrointestinal (GI) cancers, including malignancies in the gastrointestinal tract and accessory organs of digestion, represent the leading cause of death worldwide due to the poor prognosis of most GI cancers. An investigation into the potential molecular targets of prediction, diagnosis, prognosis, and therapy in GI cancers is urgently required. Proliferating cell nuclear antigen (PCNA) clamp associated factor (PCLAF), which plays an essential role in cell proliferation, apoptosis, and cell cycle regulation by binding to PCNA, is a potential molecular target of GI cancers as it contributes to a series of malignant properties, including tumorigenesis, epithelial-mesenchymal transition, migration, and invasion. Furthermore, PCLAF is an underlying plasma prediction target in colorectal cancer and liver cancer. In addition to GI cancers, PCLAF is also involved in other types of cancers and autoimmune diseases. Several pivotal pathways, including the Rb/E2F pathway, NF-κB pathway, and p53-p21 cascade, are implicated in PCLAF-mediated diseases. PCLAF also contributes to some diseases through dysregulation of the p53 pathway, WNT signal pathway, MEK/ERK pathway, and PI3K/AKT/mTOR signal cascade. This review mainly describes in detail the role of PCLAF in physiological status and GI cancers. The signaling pathways involved in PCLAF are also summarized. Suppression of the interaction of PCLAF/PCNA or the expression of PCLAF might be potential biological therapeutic strategies for GI cancers.
影响因子：
5.6
作者：
Wang Q;Wang Y;Li Y;Gao X;Liu S;Cheng J
通讯作者：
Cheng J
影响因子：
3.7
作者：
Cicek MS;Cunningham JM;Fridley BL;Serie DJ;Bamlet WR;Diergaarde B;Haile RW;Le Marchand L;Krontiris TG;Younghusband HB;Gallinger S;Newcomb PA;Hopper JL;Jenkins MA;Casey G;Schumacher F;Chen Z;DeRycke MS;Templeton AS;Winship I;Green RC;Green JS;Macrae FA;Parry S;Young GP;Young JP;Buchanan D;Thomas DC;Bishop DT;Lindor NM;Thibodeau SN;Potter JD;Goode EL;Colon CFR
通讯作者：
Colon CFR
影响因子：
4
作者：
Cha S;Park I;Jang KL
通讯作者：
Jang KL